# Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer

> **NCT00582790** · PHASE2 · TERMINATED · sponsor: **University of Wisconsin, Madison** · enrollment: 12 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** IL2
- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00582790
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-08
- **Primary completion:** 2008-08
- **Final completion:** 2008-09
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2019-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00582790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00582790, "Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00582790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*